Judith Skaptason

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

Shinji Yamazaki, Judith Skaptason, David Romero et al. · Drug Metabolism and Disposition · 2008 · 94 citations

Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone

Pei‐Pei Kung, Buwen Huang, Gang Zhang et al. · Journal of Medicinal Chemistry · 2009 · 73 citations · Full text

Pharmaceutical Science, Chemical Biology, Pharmaceutical Chemistry +16

Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model

Shinji Yamazaki, Judith Skaptason, David Romero et al. · Drug Metabolism and Disposition · 2010 · 61 citations

Identification of (<i>R</i>)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor

Devin M. Swanson, Brad M. Savall, Kevin J. Coe et al. · Journal of Medicinal Chemistry · 2016 · 35 citations · Full text

Drug Target, Pharmacotherapy, Pharmaceutical Chemistry +19

Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy

Cathy Zhang, Karen Lundgren, Zhengming Yan et al. · Molecular Cancer Therapeutics · 2008 · 12 citations

Chemoprevention Strategy, Antitumor Efficacy, Pharmacologic Properties +16